Characterisation of Restrictive Horizontal Practices under Competition Law (Part 3)
Obiter · 10.07.2026 · 47 (2)
DOI: 10.17159/fzgd7x54 ↗Kurz gefasst
Fachartikel in der Zeitschrift Obiter, online erschienen am 10.07.2026. Verfasst von Jan-Louis van Tonder. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sections 4(1)(a) and (b) of the Competition Act 89 of 1998 reflect the distinction in competition law between horizontal restrictive practices that may be evaluated either through a “rule of reason” analysis or treated as automatically unlawful under a “per se” approach. Section 4(1)(a) contemplates a “rule of reason” analysis in terms of which the anti-competitive effects of the conduct in issue must be proved and, even if such effects are demonstrated, they are susceptible to justification on technological, efficiency or pro-competitive grounds. By contrast, where the impugned conduct involves any of the restrictive horizontal practices listed in section 4(1)(b), namely, price-fixing, market division or collusive tendering, it is prohibited “per se” in that the anti-competitive effect thereof is presumed and cannot be justified on technological, efficiency or pro-competitive grounds. As is the case with bona fide agreements that are embarked upon by competitors for a legitimate purpose, commercially reasonable ancillary restraints, even when concluded between competitors, ought not to be treated as automatically infringing section 4(1)(b) without further enquiry. For these purposes, the Competition Appeal Court (CAC) in Dawn Consolidated Holdings (Pty) Ltd v Competition Commission (Dawn) has developed a well-refined test to assess whether a restraint of trade within a broader agreement, such as a joint venture, falls within the scope of the prohibitions enacted by section 4(1)(b) of the Competition Act. Part 1 critically reviews the applicable South African framework and principles relevant to characterisation as developed in American Natural Soda Ash Corporation v Competition Commission and Competition Commission v South African Breweries Ltd and assesses the approach to whether conduct is anti-competitive by object or effect under article 101 of the Treaty on the Functioning of the European Union (EU). Part 2 builds on Part 1 by reviewing and assessing key facets of characterisation that have further emerged from notable cases such as Aranda Textile Mills (Pty) Ltd v The Competition Commission of South Africa, Tourvest Holdings (Pty) Ltd v Competition Commission, Competition Commission of South Africa v Irwin & Johnson, and Competition Commission v Waco Africa (Pty) Ltd. Part 3 reviews and assesses the approach relevant to characterisation of ancillary restraints of trade as developed by the CAC in Dawn. Pursuant to section 1(3) of the Competition Act, appropriate foreign and international law may be considered when interpreting or applying the Competition Act. This is complementary to section 1(2)(a), which directs that the Competition Act must be interpreted in a manner that is consistent with the Constitution and that gives effect to the purposes set out in section 2. In light hereof, this article also considers the approaches in the United Kingdom, the EU and the United States. (Van Tonder “Characterisation of Restrictive Horizontal Practices under Competition Law (Part 1)” 2025 46(4) Obiter 872–886; Van Tonder “Characterisation of Restrictive Horizontal Practices under Competition Law (Part 2)” 2026 47(1) Obiter 1–14)
Zitieren
APA
Tonder, J. V. (2026). Characterisation of Restrictive Horizontal Practices under Competition Law (Part 3). Obiter, 47(2). https://doi.org/10.17159/fzgd7x54
Vancouver
Tonder JV. Characterisation of Restrictive Horizontal Practices under Competition Law (Part 3). Obiter. 2026;47(2). doi:10.17159/fzgd7x54
BibTeX
@article{Tonder2026,
author = {Tonder, Jan-Louis van},
title = {Characterisation of Restrictive Horizontal Practices under Competition Law (Part 3)},
journal = {Obiter},
year = {2026},
volume = {47},
number = {2},
doi = {10.17159/fzgd7x54}
}
EUVIMED